Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CHKA | P35790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3873748 | 0.97 | L3MBTL1 (0.37) | L3MBTL1ALDH1A1F2HPGDNPC1 | |
| SCHEMBL1794347 | 0.97 | — | — | |
| SCHEMBL790285 | 0.92 | — | — | |
| SCHEMBL5149419 | 0.86 | — | — | |
| Pyrrolidine SCHEMBL2830893 | 0.84 | CA2 (0.38) | ALDH1A1CA2CA1MAPTCHKA | |
| SCHEMBL28062708 | 0.82 | CA2 (0.41) | CA2CA1CHKA | |
| SCHEMBL929174 | 0.80 | L3MBTL3 (0.49) | L3MBTL1ALDH1A1 | |
| SCHEMBL1764108 | 0.78 | CA2 (0.36) | CA2CA1MAPTCHKA | |
| SCHEMBL1114107 | 0.78 | ALDH1A1 (0.39) | L3MBTL1ALDH1A1HPGDPOLBMMP1 | |
| SCHEMBL2483464 | 0.78 | ALDH1A1 (0.39) | L3MBTL1ALDH1A1HPGDPOLBMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1189061-B1 | Multifunctional erythrocyte reagent containing carbamates and uses | IMMUNOTECH SA (FR) | 2009-12-02 | — | — | EP | claimed |
| CN-1894173-A | Preparation of 18-fluoro-labeled aromatic amino acids | UNIV EBERHARD KARLS (DE) | 2007-01-10 | — | — | CN | claimed |
| CN-1382377-A | Operation for onzyme activity of protoporphyrin prooxidase in eukaryotic organism | SINGENTA PARTICIPATION AG (CH) | 2002-12-04 | — | — | CN | claimed |
| US-20020115118-A1 | Multi-functional reagent for erythrocytes | IMMUNOTECH (FR) | 2002-08-22 | — | — | US | claimed |
| WO-1995011895-A1 | N-BENZOYL-4-OXY/THIO-2-SUBSTITUTED PIPERIDINES AS SUBSTANCE-P RECEPTOR ANTAGONISTS | CIBA-GEIGY AG (CH) | 1995-05-04 | — | — | WO | claimed |
| CN-109476709-B | Methods and compositions for conferring and/or enhancing herbicide tolerance using protoporphyrinogen oxidase or variants thereof | FARMHANNONG Co.,Ltd. (KR) | 2026-05-26 | — | — | CN | disclosed |
| US-12590123-B2 | Compounds and methods for treating cancer, viral infections, and allergic conditions | WASHINGTON UNIVERSITY (US) | 2026-03-31 | — | — | US | disclosed |
| EP-3870285-B1 | SYNTHESIS OF ESUBERAPROST PRODRUGS | UNITED THERAPEUTICS CORP (US) | 2025-06-18 | — | — | EP | disclosed |
| US-20250154181-A1 | TREPROSTINIL PRODRUGS | UNITED THERAPEUTICS CORPORATION (US) | 2025-05-15 | — | — | US | disclosed |
| CN-119486739-A | α4β1/7Integrin ligand conjugated compounds and uses thereof | 阿达尔克斯制药有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119451678-A | Inhibition of histone deacetylase 6 (HDAC 6) | 艾科尼佐治疗股份有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-112566894-B | Potent inhibitors of D-amino acid oxidase (DAAO) and uses thereof | 心悦生医股份有限公司 | 2025-01-17 | — | — | CN | disclosed |
| EP-0844000-A1 | Use of alpha, omega-diarylalkane derivatives in the treatment and prevention of psychosis | SANKYO COMPANY LIMITED (JP) | 1998-05-27 | — | — | EP | disclosed |
| EP-0790235-A1 | Diaryl alkane derivatives containing an alicyclic group, their preparation and their therapeutic and prophylactic uses | SANKYO COMPANY LIMITED (JP) | 1997-08-20 | — | — | EP | disclosed |
| CN-1150820-A | Manipulation of protoporphyrinogen oxidase enzyme activity in eukaryotes | CIBA GEIGY AG (CH) | 1997-05-28 | — | — | CN | disclosed |
| US-5556864-A | TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0600717-A1 | Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis | SANKYO COMPANY LIMITED (JP) | 1994-06-08 | — | — | EP | disclosed |
| EP-0026469-B1 | DIBENZAZEPINE DERIVATIVES, THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANDOZ AG (CH) | 1984-11-28 | — | — | EP | disclosed |
| US-4360525-A | NEUROLEPTIC AGENTS, ANTIDEPRESSANTS, SLEEP PROMOTERS | SANDOZ LTD. (CH) | 1982-11-23 | — | — | US | disclosed |
| EP-0026469-A1 | Dibenzazepine derivatives, their production and pharmaceutical compositions containing them | SANDOZ AG (CH) | 1981-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154181-A1 | TREPROSTINIL PRODRUGS | TYMP, TK1, DCTPP1 | L3MBTL1 2526/4885ALDH1A1 758/4885F2 1866/4885 |
| US-12590123-B2 | Compounds and methods for treating cancer, viral infections, and allergic conditions | TMPRSS2, TMPRSS4, F2RL3 | L3MBTL1 894/4885ALDH1A1 2827/4885F2 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.